# Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia

> **NCT01158885** · PHASE2 · TERMINATED · sponsor: **Therapeutic Advances in Childhood Leukemia Consortium** · enrollment: 2 (actual)

## Conditions studied

- Minimal Residual Disease
- Leukemia, Lymphoblastic, Acute
- Leukemia, Myelogenous, Acute

## Interventions

- **DRUG:** Clofarabine
- **DRUG:** Cytarabine intravenous
- **DRUG:** Methotrexate
- **DRUG:** Intrathecal (IT) Cytarabine

## Key facts

- **NCT ID:** NCT01158885
- **Lead sponsor:** Therapeutic Advances in Childhood Leukemia Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-08
- **Primary completion:** 2012-10-24
- **Final completion:** 2012-10-24
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Study terminated for lack of accrual.
- **Last updated:** 2021-10-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01158885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01158885, "Clofarabine With Cytarabine for Patients With Minimal Residual Disease Positive Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01158885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*